Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|March 22, 2006
Datatrial Announces Partnership With Nexus Oncology
The collaboration will provide Datatrial and Nexus' clients with more effective management and delivery of oncology trials
Advertisement
Newcastle upon Tyne, United Kingdom & Raleigh, North Carolina – March 22, 2006 – Datatrial, an innovative provider of global data management solutions for the clinical research industry, announces an operational partnership with Nexus, a niche oncology contract research organization (CRO). The collaboration will provide Datatrial and Nexus' clients with more effective management and delivery of oncology trials.
As part of the agreement, Datatrial will provide Data Management and Biostatistical reporting services for Nexus, as well as Electronic Data Capture technology through its nowEDC™ and nowReport™ systems. The proprietary nowEDC™ system provides an online data collection tool focused on ease of use and efficiency at the investigative site, while providing dynamic functionality to the supporting clinical teams. The wizard-driven, XML reporting software, nowReport™, provides customers with continuous access to current trial data for precise decision making and patient safety management. Together they will provide Nexus with the tools to successfully execute and manage the most complicated oncology studies. Additionally, Datatrial will provide traditional Data Management and Biostatistical services utilizing Oracle Clinical and SAS tools.
Andrew MacGarvey, Vice President at Datatrial, commented, "Datatrial performed its first studies in the field of oncology, and has built on that experience in this complex area using our Electronic Data Capture system, nowEDC™, as well as traditional Data Management and Biostatistical services. Our relationship with Nexus Oncology allows us to provide a full range of services in this sector, and is already proving to be highly successful."
Clare Wareing, Founder and Managing Director of Nexus Oncology, added, "We are delighted to announce our partnership with Datatrial. It is a natural progression from our successful collaborations to date, and will help to ensure that Nexus Oncology continues to successfully manage and deliver its research. Applying Datatrial's strategies and solutions to our clinical trials will be a substantial asset to the biometrics process from data collection to reporting. This will benefit our client's development timelines while allowing us to manage data as effectively as possible."
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5